Skip to main content
Premium Trial:

Request an Annual Quote

MDx Firm Co-Diagnostics Buying Technologies from DNA Logix

NEW YORK (GenomeWeb News) – Molecular diagnostics Co-Diagnostics late on Friday announced an agreement with DNA Logix to acquire certain technologies for genetic analysis in the clinical, industrial, and biothreat spaces.

Sandy, Utah-based Co-Diagnostics will buy DNA Logix's technology pertaining to DNA testing with "superior sensitivity and specificity. The technology facilitates rapid assay development and significantly reduced costs for the end user," it said.

The technology was created by Brent Satterfield, founder of Bountiful, Utah-based DNA Logix. Using the acquired technology, Co-Diagnostics will develop molecular technologies based on biophysical models and statistical bioinformatics. The planned products will use PCR technology and mathematical methods to predict the presence or absence of disease or infections on the DNA level, it said on its website.

Financial and other terms of the deal were not disclosed.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.